Latest Humira biosimilar settlement provides further proof of AbbVie patent strategy’s effectiveness
With the recent announcement that it had reached a settlement in its patent dispute with Samsung Bioepis, AbbVie has scored another significant victory in efforts to delay market entry to biosimilar versions of its drug, Humira. While allowing…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.